SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced the addition of Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Weber will work with Turnstone’s SAB and management team to provide strategic, scientific, and clinical guidance to advance the Company’s pipeline of Selected TIL therapies, which are designed to selectively expand the most potent tumor-reactive T cells and extend the benefit of TILs to a wide breadth of solid tumor types.
“We are very pleased to welcome Dr. Weber to the Turnstone Scientific Advisory Board,” said Stewart Abbot, Ph.D., Turnstone. “Dr. Weber’s work has led to groundbreaking achievements in cancer immunotherapy, and he brings unique expertise and perspective to our SAB. We look forward to drawing on his extensive research and clinical experience as we continue to develop our novel Selected TIL-based pipeline and progress our lead clinical program, TIDAL-01, for people with solid tumors.”
Dr. Weber currently serves as Deputy Director of the Perlmutter Cancer Center (PCC) and Co-Director of the Melanoma Research Program at the New York University (NYU)-Langone Cancer Center. Dr. Weber is the Principal Investigator of several ongoing studies funded by the National Cancer Institute (NCI) and has been involved in a large variety of clinical trials, including protocols involving TILs and other immunotherapies for patients with melanoma. He has been the chair of the Clinical Oncology (CONC) Study Section of the NCI and of the U.S. Veterans Affairs’ Clinical Oncology Study Section. He also serves as the co-principal investigator of NYU’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the NCI. His research has been funded by RO1 grants for more than 28 years, and he has published in excess of 250 articles in top peer-reviewed journals. Dr. Weber earned his Ph.D. in molecular cell biology at The Rockefeller University and his M.D. from NYU School of Medicine.
“Turnstone is advancing a differentiated approach to TIL therapy and I am delighted to join the esteemed members of Turnstone’s SAB,” said Dr. Weber. “I believe it is becoming increasingly evident over the last decade that T cells reacting to tumor neoantigens are associated with meaningful responses. In specifically selecting and expanding these tumor-reactive T cells, Turnstone’s Selected TILs have the potential to achieve more objective responses in a wider range of solid tumors. I look forward to partnering with Turnstone to deliver the next-generation of TIL therapies to underserved patient populations.”
About Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Turnstone’s novel TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are based on the beliefs and assumptions of our management team, and on information currently available to such management team. These forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact, contained in this press release, including statements regarding future events, future financial performance, business strategy and plans, and objectives of ours for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would,” or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, levels of activity, performance or achievements of and those of our industry to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on any forward-looking statement. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. We undertake no obligation to update or revise publicly any of the forward-looking statements after the date hereof to conform the statements to actual results or changed expectations except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. This press release discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the uses for which they are being studied. Trade names, trademarks and service marks of other companies appearing in this press release are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this press release appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames. This press release is not an offer to sell our securities and it is not soliciting offers to buy securities nor shall there be any sale of our securities in any jurisdiction where the offer, solicitation or sale is not permitted.
Contact
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
